anti- ALX1 antibody FNab00352
Background:
Sequence-specific DNA-binding transcription factor that binds palindromic sequences within promoters and may activate or repress the transcription of a subset of genes(PubMed:9753625, PubMed:8756334). Most probably regulates the expression of genes involved in the development of mesenchyme-derived craniofacial structures. Early on in development, it plays a role in forebrain mesenchyme survival(PubMed:20451171). May also induce epithelial to mesenchymal transition(EMT) through the expression of SNAI1(PubMed:23288509).
Clonality:
polyclonal
Classification:
Primary antibody
Alternative names:
ALX homeobox 1, ALX homeobox protein 1, ALX1, CART 1, CART1, Cartilage homeoprotein 1
Specificity:
Human, Mouse
Host:
Rabbit
Isotype:
IgG
Immunogen:
ALX homeobox 1
Purification:
Immunogen affinity purified
Purity:
≥95% as determined by SDS-PAGE
Calculated molecular weight:
37 kDa
Form:
liquid
Applications:
ELISA, WB
Recommended dilution:
WB: 1:200-1:2000
Storage:
PBS with 0.02% sodium azide and 50% glycerol pH 7.3,-20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
More info:
Email: info@sobekbio.com
Orders:
Email: orders@sobekbio.com
Fine Biotech is an ISO9001:2008 Certified Company,offers a full line of quality research kits,which include ELISA Kits,related ELISA assistant reagents and more high quality antibodies, recombinant proteins. Fine Biotech technical support are delicated to providing with professional and friendly assistance for our customers. Strict and multiple quality control ensure that our products continue to successfully supply for the international market. Moreover, we strive to continuously improve the customer experience through comprehensive technical support. High quality,rapid turnaround and personal support for all FineTest services are guaranteed. Should you have any problems,or any ideas on ways that we can improve our service,please feel free to call upon us.Thank you for your interest in FineTest products and we look forward to supplying you in the near future.